Patient and economic burdens of postherpetic neuralgia in China

References

• Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6):e004833. doi:10.1136/bmjopen-2014-004833
   PubMed Web of Science ®Google Scholar
• Schmader K. Herpes zoster and postherpetic neuralgia in older adults. Clin Geriatr Med. 2007;23(3):615–632, vii-viii. doi:10.1016/j.cger.2007.03.003
   PubMed Web of Science ®Google Scholar
• Dworkin RH, Gnann JW Jr., Oaklander AL, Raja SN, Schmader KE, Whitley RJ. Diagnosis and assessment of pain associated with herpes zoster and postherpetic neuralgia. J Pain. 2008;9(1 Suppl 1):S37–S44. doi:10.1016/j.jpain.2007.10.00818166464
   PubMed Web of Science ®Google Scholar
• International Association for the Study of Pain. IASP taxonomy. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698. Accessed 95, 2018.
   Google Scholar
• Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113–1123. doi:10.1111/j.1468-1331.2010.02999.x20402746
   PubMed Web of Science ®Google Scholar
• Dworkin RH, O’Connor AB, Audette J, et al. Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc. 2010;85(3 Suppl):S3–S14. doi:10.4065/mcp.2009.0649
   PubMed Web of Science ®Google Scholar
• Argoff CE. Review of current guidelines on the care of postherpetic neuralgia. Postgrad Med. 2011;123(5):134–142. doi:10.3810/pgm.2011.09.246921904096
   PubMed Web of Science ®Google Scholar
• Snedecor SJ, Sudharshan L, Cappelleri JC, et al. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68(7):900–918. doi:10.1111/ijcp.1241124698515
   PubMed Web of Science ®Google Scholar
• Zhu Q, Zheng H, Qu H, et al. Epidemiology of herpes zoster among adults aged 50 and above in Guangdong, China. Hum Vaccin Immunother. 2015;11(8):2113–2118. doi:10.1080/21645515.2015.101667226020733
   PubMed Web of Science ®Google Scholar
• Li Y, An Z, Yin D, et al. Disease burden due to herpes zoster among population aged >/=50 years old in China: a community based retrospective survey. PLoS One. 2016;11(4):e0152660. doi:10.1371/journal.pone.015266027055179
   PubMed Web of Science ®Google Scholar
• Yang F, Yu S, Fan B, et al. The epidemiology of herpes zoster and postherpetic neuralgia in China: results from a non-interventional, cross-sectional study. Pain Ther. Epub 2019 Jun 19. doi:10.1007/s40122-019-0127-z
   PubMed Web of Science ®Google Scholar
• Johnson RW, Bouhassira D, Kassianos G, Leplege A, Schmader KE, Weinke T. The impact of herpes zoster and post-herpetic neuralgia on quality-of-life. BMC Med. 2010;8:37. doi:10.1186/1741-7015-8-3720565946
   PubMed Web of Science ®Google Scholar
• Gater A, Uhart M, McCool R, Preaud E. The humanistic, economic and societal burden of herpes zoster in Europe: a critical review. BMC Public Health. 2015;15:193. doi:10.1186/s12889-015-1514-y25880058
   PubMed Web of Science ®Google Scholar
• Drolet M, Levin MJ, Schmader KE, et al. Employment related productivity loss associated with herpes zoster and postherpetic neuralgia: a 6-month prospective study. Vaccine. 2012;30(12):2047–2050. doi:10.1016/j.vaccine.2012.01.04522285632
   PubMed Web of Science ®Google Scholar
• Meyers JL, Madhwani S, Rausch D, Candrilli SD, Krishnarajah G, Yan S. Analysis of real-world health care costs among immunocompetent patients aged 50 years or older with herpes zoster in the United States. Hum Vaccin Immunother. 2017;13(8):1861–1872. doi:10.1080/21645515.2017.132437328605285
   PubMed Web of Science ®Google Scholar
• Matthews S, De Maria A, Passamonti M, et al. The economic burden and impact on quality of life of herpes zoster and postherpetic neuralgia in individuals aged 50 years or older in Italy. Open Forum Infect Dis. 2019;6(2):ofz007. doi:10.1093/ofid/ofz12530793003
   PubMedGoogle Scholar
• Schmidt-Ott R, Schutter U, Simon J, et al. Incidence and costs of herpes zoster and postherpetic neuralgia in German adults aged >/=50 years: A prospective study. J Infect. 2018;76(5):475–482. doi:10.1016/j.jinf.2018.02.00129428228
   PubMed Web of Science ®Google Scholar
• Rampakakis E, Pollock C, Vujacich C, et al. Economic burden of herpes zoster (“culebrilla”) in Latin America. Int J Infect Dis. 2017;58:22–26. doi:10.1016/j.ijid.2017.02.02128267595
   PubMed Web of Science ®Google Scholar
• Zostavax® (Zoster Vaccine Live) suspension for subcutaneous injection prescribing information. Merck & Co., Inc. Whitehouse Station, NJ; 4, 2018 Available from: http://www.merck.com/product/usa/pi_circulars/z/zostavax/zostavax_pi2.pdf. Accessed 66, 2019.
   Google Scholar
• Shingrix® (Zoster Vaccine Recombinant ASfIIpi). GlaxoSmithKline, Research Triangle Park, NC; 10 2017 Available from: https://gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF. Accessed 66, 2019.
   Google Scholar
• Centers for Disease Control and Prevention. Recommended immunization schedule for adults aged 19 years or older, United States; 2018 Available from: https://www.cdc.gov/vaccines/schedules/downloads/adult/adult-combined-schedule.pdf. Accessed 66, 2019.
   Google Scholar
• Berger ML, Sox H, Willke RJ, et al. Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE special task force on real-world evidence in health care decision making. Value Health. 2017;20(8):1003–1008. doi:10.1016/j.jval.2017.08.301928964430
   PubMed Web of Science ®Google Scholar
• Cleeland CS, Ryan KM. Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore. 1994;23(2):129–138.8080219
   PubMedGoogle Scholar
• Hays R, Stewart A. Sleep measures In: Stewart A, Ware J, editors. Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC: Duke University Press; 1992:235–259.
   Google Scholar
• The EuroQol Group. EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199–208.10109801
   PubMed Web of Science ®Google Scholar
• Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4:353–365. doi:10.2165/00019053-199304050-0000610146874
   PubMed Web of Science ®Google Scholar
• Reilly MC. Work Productivity and Activity Impairment Questionnaire: Specific Health Problem V2.0 (WPAI:SHP). Available from: http://www.reillyassociates.net/WPAI_SHP.html. Accessed 95, 2018.
   Google Scholar
• Dworkin RH, Turk DC, Farrar JT, et al. Core outcome measures for chronic pain clinical trials: IMMPACT recommendations. Pain. 2005;113:9–19. doi:10.1016/j.pain.2004.09.01215621359
   PubMed Web of Science ®Google Scholar
• Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the Medical Outcomes Study Sleep. Sleep Med. 2005;6(1):41–44. doi:10.1016/j.sleep.2004.07.00615680294
   PubMed Web of Science ®Google Scholar
• Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35(11):1095–1108.9366889
   PubMed Web of Science ®Google Scholar
• Chinese Ministry of Health. Available from: http://www.nhfpc.gov.cn/mohwsbwstjxxzx/s7967/201808/4f106ab85862461c8b0a3f24f86f7c37.shtml. Accessed 95, 2018.
   Google Scholar
• Lofland JH, Pizzi L, Frick KD. A review of health-related workplace productivity loss instruments. Pharmacoeconomics. 2004;22(3):165–184. doi:10.2165/00019053-200422030-0000314871164
   PubMed Web of Science ®Google Scholar
• National Bureau of Statistics of China. China statistical yearbook; 2016; Available from: http://www.stats.gov.cn/tjsj/ndsj/2016/indexeh.htm. Accessed 95, 2018.
   Google Scholar
• OANDA. Historical exchange rates. Available from: https://www.oanda.com/currency/average. Accessed 95, 2018.
   Google Scholar
• The R project for statistical computing. Available from: https://www.r-project.org/. Accessed 95, 2018.
   Google Scholar
• van Seventer R, Sadosky A, Lucero M, Dukes E. A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia (PHN). Age Ageing. 2006;35(2):132–137. doi:10.1093/ageing/afj04816431855
   PubMed Web of Science ®Google Scholar
• Drolet M, Brisson M, Schmader KE, et al. The impact of herpes zoster and postherpetic neuralgia on health-related quality of life: a prospective study. Can Med Assoc J. 2010;182(16):1731–1736. doi:10.1503/cmaj.09171120921251
   PubMed Web of Science ®Google Scholar
• Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study. Health Qual Life Outcomes. 2014;12:92. doi:10.1186/1477-7525-12-9224920439
   PubMed Web of Science ®Google Scholar
• Mizukami A, Sato K, Adachi K, et al. Impact of herpes zoster and post-herpetic neuralgia on health-related quality of life in Japanese adults aged 60 years or older: results from a prospective, observational cohort study. Clin Drug Investig. 2018;38(1):29–37. doi:10.1007/s40261-017-0581-5
   PubMed Web of Science ®Google Scholar
• Lee DH, Park JE, Yoon DM, Yoon KB, Kim K, Kim SH. Factors associated with increased risk for clinical insomnia in patients with postherpetic neuralgia: a retrospective cross-sectional study. Pain Med. 2016;17(10):1917–1922. doi:10.1093/pm/pnw06627073226
   PubMedGoogle Scholar
• Smith MT, Haythornthwaite JA. How do sleep disturbance and chronic pain inter-relate? Insights from the longitudinal and cognitive-behavioral clinical trials literature. Sleep Med Rev. 2004;8(2):119–132. doi:10.1016/S1087-0792(03)00044-315033151
   PubMed Web of Science ®Google Scholar
• Edwards RR, Almeida DM, Klick B, Haythornthwaite JA, Smith MT. Duration of sleep contributes to next-day pain report in the general population. Pain. 2008;137(1):202–207. doi:10.1016/j.pain.2008.01.02518434020
   PubMed Web of Science ®Google Scholar
• Finan PH, Goodin BR, Smith MT. The association of sleep and pain: an update and a path forward. J Pain. 2014;14(12):1539–1552. doi:10.1016/j.jpain.2013.08.007
   Web of Science ®Google Scholar
• Szende A, Janssen B. Population norms for the EQ-5D. In: Cabases JM, Szende A, Janssen B, editors. Self-reported population health: an international perspective based on EQ-5D Dordrecht: Springer; 2014:19–30.
   Google Scholar
• Coretti S, Ruggeri M, McNamee P. The minimum clinically important difference for EQ-5D index: a critical review. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):221–233. doi:10.1586/14737167.2014.89446224625040
   PubMed Web of Science ®Google Scholar
• Doth AH, Hansson PT, Jensen MP, Taylor RS. The burden of neuropathic pain: a systematic review and meta-analysis of health utilities. Pain. 2010;149(2):338–344. doi:10.1016/j.pain.2010.02.03420227832
   PubMed Web of Science ®Google Scholar
• Pickard AS, Neary MP, Cella D. Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes. 2007;5:70. doi:10.1186/1477-7525-5-7018154669
   PubMed Web of Science ®Google Scholar
• Coteur G, Feagan B, Keininger DL, Kosinski M. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn’s disease. Aliment Pharmacol Ther. 2009;29(9):1032–1041. doi:10.1111/j.1365-2036.2009.03966.x19222413
   PubMed Web of Science ®Google Scholar
• Zanini A, Aiello M, Adamo D, et al. Estimation of minimal clinically important difference in EQ-5D visual analog scale score after pulmonary rehabilitation in subjects with COPD. Respir Care. 2015;60(1):88–95. doi:10.4187/respcare.0327225336531
   PubMed Web of Science ®Google Scholar
• Feng Q, Yeung W-J-J, Wang Z, Zeng Y. Age of retirement and human capital in an aging China, 2015–2050. Eur J Popul. 2018;35(1):29–62. doi:10.1007/s10680-018-9467-3
   PubMed Web of Science ®Google Scholar
• Stewart WF, Ricci JA, Chee E, Morganstein D, Lipton R. Lost productive time and cost due to common pain conditions in the US workforce. JAMA. 2003;290(18):2443–2454. doi:10.1001/jama.290.18.244314612481
   PubMed Web of Science ®Google Scholar
• Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. J Med Econ. 2013;16(1):85–95. doi:10.3111/13696998.2012.72954822970839
   PubMedGoogle Scholar
• Dubinsky RM, Kabbani H, El-Chami Z, Boutwell C, Ali H. Practice parameter: treatment of postherpetic neuralgia. An evidence-based report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2004;63:959–965. doi:10.1212/01.wnl.0000140708.62856.7215452284
   PubMed Web of Science ®Google Scholar
• Gialloreti LE, Merito M, Pezzotti P, et al. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: a retrospective, population-based study. BMC Infect Dis. 2010;10:230. doi:10.1186/1471-2334-10-23020682044
   PubMed Web of Science ®Google Scholar
• Nilsson J, Cassel T, Lindquist L. Burden of herpes zoster and post-herpetic neuralgia in Sweden. BMC Infect Dis. 2015;15:215. doi:10.1186/s12879-015-0951-726002038
   PubMedGoogle Scholar
• Cheong C, Lee TJ. Prevalence and healthcare utilization of herpes zoster and postherpetic neuralgia in South Korea: disparity among patients with different immune statuses. Epidemiol Health. 2014;36:e2014012. doi:10.4178/epih/e201401225119454
   PubMedGoogle Scholar